The search for an effective HFpEF treatment continues

Nature Reviews Cardiology, Published online: 16 September 2019; doi:10.1038/s41569-019-0277-zThe PARAGON-HF trial indicates that sacubitril–valsartan does not have a significant benefit in patients with heart failure with preserved ejection fraction (HFpEF) for reducing hospitalizations for heart failure and death from cardiovascular causes. However, the trial suggests a potential benefit in patients with low left ventricular ejection fraction and in women.
Source: Nature Reviews Cardiology - Category: Cardiology Authors: Source Type: research